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Monomeric RGD peptides show unspecific fluid-phase uptake
in cells, whereas multimeric RGD peptides are thought to be
internalized by integrin-mediated endocytosis. However, a po-
tential correlation between uptake mechanism and molecular
mass has been neglected so far. A dual derivatization of pep-
tide c(RGDw(7Br)K) was performed to investigate this. A fluo-
rescent probe was installed by chemoselective Suzuki–Miyaura
cross-coupling of the 7-bromotryptophan and a poly(ethylene
glycol) (PEG) linker was attached to the lysine residue. Flow cy-
tometry and live cell imaging confirmed unspecific uptake of
the small, non-PEGylated peptide, whereas the PEG5000 peptide
conjugate unveiled a selective internalization by M21 cells
overexpressing avb3 and no uptake in av-deficient M21L cells.
Integrins play a crucial role in cell adhesion and signaling. In
particular, RGD-binding integrins emerged as targets for selec-
tive tumor therapy as they regulate processes like apoptosis,
metastasis, or angiogenesis, and are overexpressed on malig-
nant cells, while being downregulated on most healthy
cells.[1, 2] Since their first discovery in the late 1980s[3] a variety
of ligands targeting integrins like avb3 were developed. How-
ever, prominent small-molecule ligands as cilengitide,[4]
c(RGDf(NMe)V), failed in clinical trials also due to its ambiguous
role in angiogenesis.[5] Nevertheless, 18F-galacto-RGD and deriv-
atives are currently under clinical investigation and show
promising results as a positron emission tomography tracer.[6]
Especially because much is known about the relationship be-
tween structure and activity for RGD ligands, they represent a
versatile and easily accessible toolkit for drug targeting. In this
context, the internalization pathway into the target cell is an
important issue.
As shown previously, monomeric RGD peptides undergo a
fluid-phase rather than a clathrin-dependent uptake.[7] Interest-
ingly, a tetrameric regioselective addressable functionalized
template peptide (RAFT-RGD-Cy5) does not only provide
higher affinity toward avb3 but was shown to undergo clathrin-
mediated internalization.[8] Thus, multivalent RGD peptides are
considered superior for in vivo studies. However, in a contra-
dictory report Ga-labeled trimeric and monomeric ligands were
compared. It was found that improved in vitro properties of
multimers were not consistent with better in vivo per-
formance.[9] These case studies demonstrate the complex inter-
action patterns and show that predictions of translation from
in vitro to in vivo are not straightforward.
In the last decades, a variety of RGD-drug conjugates has
been synthesized for targeted drug delivery.[10] However, the
pathway of uptake was only studied sparingly and reports are
conflicting. For example, studies by us revealed colocalization
of an RGD-cryptophycin-52 conjugate with lysosomes in WM-
115 cells[11] (overexpressing avb3) and in contrast, an RGD-cryp-
tophycin-55 conjugate was internalized both by M21 (over-
expressing avb3) and M21L (av knockout) cells.
[12] Likewise,
cytotoxic RGD-a-amanitin conjugates did not provide specific
uptake.[13] It was further demonstrated that a monomeric RGD-
doxorubicin conjugate afforded good binding affinities toward
avb3 in a cell adhesion assay, but was not internalized.
[14] Addi-
tionally, RGD conjugates tend to accumulate on the cell surface
as described for c(diketopiperazine-RGD)-sCy5 conjugates.[15]
However, in vivo experiments confirmed that numerous multi-
valent RGD conjugates are associated with improved uptake at
tumor sites.[16,17] These findings indicate that integrin-mediated
endocytosis is favored for peptides with multifold RGD sites.
We wondered whether the route of internalization solely
correlates with multivalency or whether it might be affected
by merely increasing the size of a monomeric RGD peptide. As
this has not yet been investigated to the best of our knowl-
edge, we synthesized monomeric RGD peptides differing in
size and investigated a potential correlation with the mode of
uptake.
c(RGDw(Br)V)-derived peptides containing a halogenated d-
Trp residue w(Br) were chosen as an intermediate for late-
stage dual modification. Halotryptophans can selectively be
synthesized by biocatalytic halogenation effecting regioselec-
tive bromination of the indole ring. They represent versatile
handles for chemoselective installation of aryl moieties by
cross-coupling reactions, which can eventually be used to gen-
erate fluorescent probes.[18–20] In particular, a large aromatic
system as in the pyrene derivative (1) permits an excitation
(lex : 365 nm) suitable for biological applications (Figure S1 in
the Supporting Information). Structure–activity relationship
studies on c(RGDfV) disclosed that any amino acid can be in-
corporated instead of valine without significantly compromis-
ing bioactivity.[21,22]
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This allows for the use of lysine in this position, enabling a
dual, chemoselective late-stage modification using bromotryp-
tophan for cross-coupling and lysine for nucleophilic substitu-
tion. PEGylation has become a popular method to increase
blood circulation times, enhance stability toward enzymatic
degradation and bioavailability.[24,25] For our experiments, a
5 kDa PEG linker was attached to increase the size relative to
peptide 1. The crude peptide was treated with 4m HCl/diox-
ane to selectively cleave the Boc protecting group. The pep-
tide was purified by RP-HPLC before addition of the NHS-acti-
vated PEG moiety and the PEGylated intermediate was purified
prior to Pbf cleavage, as separation of unreacted PEG and PEG-
ylated peptide could only be achieved at this stage. Precipita-
tion by diethyl ether after removal of protecting groups gave
peptide 2 (Scheme 1).
Affinities toward isolated integrins avb3 and a5b1 were deter-
mined in a competitive ELISA (Table 1). Peptide 1 shows some-
what decreased affinity toward avb3 relative to the reference
cilengitide (3), but an improved selectivity over a5b1. Interest-
ingly, peptide 2 exhibits similar affinities toward avb3 in com-
parison with reference peptide 3. As demonstrated previously,
substitution of valine by lysine does not have a major impact
on the affinity.[22] Previous studies have demonstrated in-
creased as well as decreased affinity for peptides modified at
lysine with different spacers,[26,27] chelators,[28] or peptides with
short PEG linkers.[29,30] Loss in affinity can mostly be ascribed to
the steric bulk of conjugates that hinder interactions with the
binding pocket. However, larger molecules may have a greater
ability to interact unspecifically with the protein surface at
more sites and thus, decrease dissociation leading eventually
to apparent affinity.[31]
Cellular internalization was studied in vitro. M21 cells overex-
press avb3, whereas the variant M21L lacks av and thus does
not express av integrins.
[12] As described previously, uptake of
monomeric RGD peptides is fluid-phase dependent,[7, 8] where-
as for multimeric peptides internalization is clathrin-depen-
dent.[8] We investigated by flow cytometry (FC) as a quantita-
tive method and live cell imaging as a qualitative method to
which extent molecular size can influence cellular uptake.
For flow cytometry studies, cells (2V106) were incubated
with peptides (30 mm) for 0, 10, or 30 min, washed with buffer
and analyzed. Interestingly, the 0 min samples already show
strong fluorescence for both cell lines that increases slightly
with longer incubation times (Figure 1A). As M21L cells do not
present integrin avb3, uptake of peptide 1 proceeds in an in-
tegrin-independent fashion.[7] The large shift between the neg-
ative control (no peptide) and the 0 min sample is caused by
ionic interactions of positively charged Arg side chains with
negatively charged phospholipids of the membrane resulting
in an accumulation of RGD peptides on the cell surface.[15, 32]
Therefore, the localization of peptides was further studied by
live cell imaging. Cells were grown overnight on glass-slip
chambers and first counterstained with LysoTracker Red DND-
99 before incubation with peptide (5 mm) for 10 min. Careful
but thorough washing steps were performed prior to analysis
by confocal microscopy. Care was taken not to detach the
semi-adherent M21L cells which lack av integrins responsible
for adherence. As shown in Figure 1B, peptide 1 is hardly inter-
nalized and shows strong interaction with the cell membrane.
Moreover, the peptide present inside the cell is not colocalized
with lysosomes indicating integrin-independent uptake like re-
ported previously.[10,23]
In contrast, flow cytometry reveals significant fluorescence
for peptide 2 in M21 cells but not for av deficient M21L cells
(Figure 2A). Contrary to peptide 1, the negative control (no
peptide) largely overlaps with the 0 min samples. Fluorescence
imaging confirmed the presence of peptide inside the cells by
z-stacking (Figure S2). Furthermore, peptide 2 colocalizes large-
ly with lysosomes (Figure 2B). As peptide 2 is barely found
inside M21L cells, integrin-mediated endocytosis can be con-
cluded. Other internalization studies with a 10 kDa PEGylated
peptide were unsuccessful : no peptide fluorescence was de-
tected during live cell imaging or flow cytometry (Figure S3).
We assume that this conjugate is either highly prone to bind
to residual serum proteins still present from cultivation or the
larger PEG shields integrin binding.[33]
An additional negative control experiment was performed to
support integrin-mediated endocytosis for peptide 2. Integrin
avb3 was incubated with a monoclonal anti-avb3 antibody for
Scheme 1. Dual late-stage functionalization of RGD peptides by cross-cou-
pling and PEGylation. Cross-coupling was performed similarly as described
previously.[23] The tBu protecting group is cleaved under the applied reaction
conditions, which does not cause any side reactions during PEGylation.
sSPhos= sodium 2’-dicyclohexylphosphino-2,6-dimethoxy-1,1’-biphenyl-3-
sulfonate hydrate; DIPEA=N,N-diisopropylethylamine; TFA= trifluoroacetic
acid; TIS= triisopropylsilane; NHS=N-hydroxysuccinimide.
Table 1. Affinities determined by an ELISA using purified, isolated integ-
rins.
No. Sequence IC50 [nm] Ratio
avb3 a5b1
1 c(RGDw(pyren-1-yl)V) 5.11:0.90 2079:237 1:41
2 c(RGDw(pyren-1-yl)K(PEG5000)) 0.88:0.03 73.6:10.7 1:84
3 c(RGDf(NMe)K) 0.54:0.02 15.4:4.0 1:29
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15 min on ice to block but not internalize avb3 integrins. Sub-
sequent incubation with peptides 1 and 2 gave significant
fluorescence for peptide 1, yet not for 2 (Figure S4). Further-
more, incubation of peptide 1 at 37 and 4 8C, respectively,
resulted in significantly decreased uptake at 4 8C (Figure S5),
which again supports specific uptake.
These results strongly support that in vitro integrin-mediat-
ed endocytosis for monomeric RGD peptides can be triggered
by attaching a PEG linker. We hypothesize that steric and phys-
icochemical effects contribute to this switch in uptake path-
way. Similar to findings that particle size influences whether
endocytosis is clathrin- or caveolae-mediated,[34] the increased
Figure 1. Uptake studies with peptide 1. A) Flow cytometry analysis after incubation of cells with peptide 1 (30 mm) for 0 min (blue), 10 min (orange), and
30 min (green). No peptide was added in the negative control (red). B) M21 and M21L cells were stained with LysoTracker Red DND-99 and incubated for
10 min with peptide 1 (5 mm) prior to fluorescence microscopy. In combination both experiments clearly show an unspecific, fluid-phase uptake of peptide 1.
Figure 2. Internalization studies with peptide 2. A) For flow cytometry peptide 2 (30 mm) was incubated with cells for 0 min (blue), 10 min (orange), and
30 min (green). No peptide was added in the negative control (red). Analysis revealed an uptake of peptide 2 only by M21 cells. B) Live cell imaging of pep-
tide 2 confirmed specific uptake only for M21 cells. For a better signal-to-noise ratio higher concentrations of peptide 2 (10 mm) were applied. The gain was
adjusted in channel 1 to ensure the absence of peptide 2 in M21L cells. White spots in merged channels represent colocalization with lysosome.
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size of peptide 2 could favor integrin-mediated over a fluid-
phase uptake. However, the hydrodynamic radius of a 5 kDa
PEG (2.3 nm) is only slightly increased in comparison with a
10 kDa dextran (1.9 nm), which is commonly applied as a fluid-
phase marker.[35] Therefore, the PEG linker might also minimize
ionic interactions with the membrane preventing an accumula-
tion on the cell membrane or enhances conformational
changes of the integrin and thus, promote internalization. It
also can be envisaged that upon binding of PEGylated peptide
its local concentration increases initiating self-assembly and
thus, creating a multivalent ligand.[36] Despite the uncertainties
as to why PEGylation induces integrin-mediated internalization,
these results question whether multivalency is the ultimate
prerequisite for integrin-mediated endocytosis.
In summary, dual late-stage functionalized RGD peptides
were synthesized to elucidate the influence of size for integrin-
mediated endocytosis. Bromotryptophan as a non-canonical
amino acid and lysine served as platforms to chemoselectively
introduce a fluorescent probe and PEG linker. Interestingly,
PEGylation of a monomeric RGD peptide effects integrin-medi-
ated endocytosis and presents a new approach to obtain mon-
omeric conjugates suitable for specific targeting.
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